Sugi Predict

Sugi Predict / Compounds / SCHEMBL19463155

SCHEMBL19463155

SCHEMBL19463155

COC(=O)c1nccc(Br)c1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ KMT2A Q03164 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ THRB P10828 2/20 0.46
▸ THRA P10827 1/20 0.46
▸ MAPT P10636 3/20 0.45
▸ TP53 P04637 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27556291 0.86 THRA (0.50) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL30781547 0.86 THRA (0.50) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL25037143 0.84 LMNA (0.53) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL31601616 0.84 LMNA (0.53) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL5583641 0.84 LMNA (0.53) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL23655236 0.82 LMNA (0.49) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL4703291 0.82 HPGD (0.58) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL6372798 0.80 LMNA (0.55) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL31636486 0.79 ALDH1A1 (0.51) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL21012569 0.79 PTGER4 (0.50) LMNAHPGDALDH1A1USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119365451-A Heterocyclic compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-01-24 — — CN disclosed
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. 2025-01-16 — — US disclosed
EP-4399210-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES Black Diamond Therapeutics, Inc. (US) 2024-07-17 — — EP disclosed
CN-118159537-A 6-Aza-quinoline derivatives and related uses 黑钻治疗公司 2024-06-07 — — CN disclosed
US-11628161-B2 Isoindoline derivative, pharmaceutical composition and use thereof KANGPU BIOPHARMACEUTICALS, LTD. (CN) 2023-04-18 — — US disclosed
WO-2023039505-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2023-03-16 — — WO disclosed
US-11337964-B2 Isoindoline derivative, pharmaceutical composition and use thereof KANGPU BIOPHARMACEUTICALS, LTD. (CN) 2022-05-24 — — US disclosed
US-20220152002-A1 ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF KANGPU BIOPHARMACEUTICALS, LTD. (CN) 2022-05-19 — — US disclosed
EP-3590924-B1 NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF KANGPU BIOPHARMACEUTICALS LTD (CN) 2021-10-27 — — EP disclosed
EP-3478693-B1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF QPEX BIOPHARMA INC (US) 2021-07-21 — — EP disclosed
US-20200325154-A1 ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION ACTELION PHARMACEUTICALS LTD (CH) 2020-10-15 — — US disclosed
US-20200061033-A1 NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF KANGPU BIOPHARMACEUTICALS, LTD. (CN) 2020-02-27 — — US disclosed
WO-2019204419-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF THE MEDICINES COMPANY (SAN DIEGO), LLC (US) 2019-10-24 — — WO disclosed
EP-3442970-A1 ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION Idorsia Pharmaceuticals Ltd (CH) 2019-02-20 — — EP disclosed
WO-2017179002-A1 ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION ACTELION PHARMACEUTICALS LTD (CH) 2017-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11337964-B2 Isoindoline derivative, pharmaceutical composition and use thereof PDE4A, PDE4B, PDE4C LMNA 4427/4885HPGD 80/4885KMT2A 4184/4885
US-20200325154-A1 ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION MT-CO3, UQCRC1, MT-ND3 LMNA 917/4885HPGD 578/4885KMT2A 3496/4885
US-20200061033-A1 NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF PDE4A, PDE4B, PDE4C LMNA 4404/4885HPGD 122/4885KMT2A 4304/4885
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES TOP2A, TOP2B, UGT2B7 LMNA 2740/4885HPGD 722/4885KMT2A 659/4885
US-11628161-B2 Isoindoline derivative, pharmaceutical composition and use thereof PDE4A, PDE4B, PDE4C LMNA 4427/4885HPGD 80/4885KMT2A 4184/4885
US-20220152002-A1 ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF PDE4A, PDE4B, PDE4C LMNA 4469/4885HPGD 81/4885KMT2A 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.